IO Biotech is a clinical stage biotech company developing disruptive immune therapies i.e. Immune regulating vaccines located in Copenhagen, Denmark

IO Biotech was founded in December 2014 as a spin out from the Centre for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital, Denmark. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic products

Focused on development of immunological treatment of cancer with a research profile based on successful R&D discoveries, translated into numerous clinical trials

Proven track record of progressing preclinical and clinical compounds

  • Two lead vaccine targeting IDO and PD-L1 are in clinical development
  • Several compounds finalizing preclinical phase
IO Biotech is managed by a experienced management team within immunology and oncology and supported with world class advisors

IO Biotech is a privately held company with a solid financial position funded by experienced investors: Lundbeckfonden Emerge, Novo Seeds & Sunstone.